Last reviewed · How we verify
LiRIS low dose and LiRIS high dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
LiRIS low dose and LiRIS high dose (LiRIS low dose and LiRIS high dose) — Allergan.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LiRIS low dose and LiRIS high dose TARGET | LiRIS low dose and LiRIS high dose | Allergan | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LiRIS low dose and LiRIS high dose CI watch — RSS
- LiRIS low dose and LiRIS high dose CI watch — Atom
- LiRIS low dose and LiRIS high dose CI watch — JSON
- LiRIS low dose and LiRIS high dose alone — RSS
Cite this brief
Drug Landscape (2026). LiRIS low dose and LiRIS high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/liris-low-dose-and-liris-high-dose. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab